General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting services, insurance costs, travel expenses and direct and allocated facility costs not otherwise included in research and development expenses.

filing / Aug 6, 2026 / receipt

▪ costs of outside consultants, including their fees, and related travel expenses; ▪ expenses to acquire technologies, such as intellectual property, to be used in research and development including in-process research and development ("IPR&D") that has no alternative future use at the time of asset acquisitions; ▪ costs related to compliance with quality and regulatory requirements; and ▪ facilities, depreciat

filing / Aug 6, 2026 / receipt

In connection with entering into the Candid Merger Agreement in the first quarter of 2026, the Company incurred severance charges of approximately $ 2.3 million of which $ 1.6 million was included in research and development expenses and $ 0.7 million was included in general and administrative expenses, with such amounts reflected in the condensed consolidated statements of operations and comprehensive income (loss).

filing / Aug 6, 2026 / receipt

Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.

filing / Aug 6, 2026 / receipt

On May 2, 2025, the Company approved a workforce reduction to focus resources on the Company’s lead program, RLYB116, and its preclinical development programs.

filing / Aug 6, 2026 / receipt

General and administrative expenses also include legal fees relating to intellectual property and corporate matters, professional fees paid for accounting, auditing, tax and consulting services, insurance costs, travel expenses and direct and allocated facility costs not otherwise included in research and development expenses.

filing / May 13, 2026 / receipt

▪ costs of outside consultants, including their fees, and related travel expenses; ▪ expenses to acquire technologies, such as intellectual property, to be used in research and development including in-process research and development ("IPR&D") that has no alternative future use at the time of asset acquisitions; ▪ costs related to compliance with quality and regulatory requirements; and ▪ facilities, depreciat

filing / May 13, 2026 / receipt

In connection with entering into the Merger Agreement and the potential Merger, the Company incurred severance charges of approximately $ 2.3 million of which $ 1.6 million was included in research and development expenses and $ 0.7 million was included in general and administrative expenses, with such amounts reflected in the condensed consolidated statements of operations and comprehensive loss.

filing / May 13, 2026 / receipt

Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.

filing / May 13, 2026 / receipt

On May 2, 2025, the Company approved a workforce reduction to focus resources on the Company’s lead program, RLYB116, and its preclinical development programs.

filing / May 13, 2026 / receipt